Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Janssen
PREPULSID® 1 mg/mL SCHEDULING STATUS: Schedule 4. PROPRIETARY NAME (and dosage form): PREPULSID ® 1 mg/mL suspension. COMPOSITION Each mL contains 1,039 mg cisapride monohydrate equivalent to 1 mg cisapride anhydrous. Preservatives: methylparaben 0,18% m/v and propylparaben 0,02% m/v. PHARMACOLOGICAL CLASSIFICATION A. 11 Medicines acting on the gastrointestinal tract. PHARMACOLOGICAL ACTION IN ANIMALS In isolated organs PREPULSID prevents gastric atony and enhances gastric peristaltic activity, antroduodenal co- ordination and small and large bowel motility. In dogs PREPULSID enhances digestive antroduodenal motility and co- ordination, accelerates gastric emptying, increases small bowel propulsive contractions and shortens intestinal transit time. Gastric secretion is not affected. The mechanism of action of PREPULSID is mainly due to an enhancement of the physiological release of acetylcholine at the myenteric plexus level. PREPULSID does not induce muscarinic or nicotinic receptor stimulation, nor does it inhibit acetylcholinesterase activity. In vitro studies have shown that cisapride has serotonin (5-HT 4 ) receptor agonist activity in the colon. IN MAN GASTROINTESTINAL MOTILITY: Oesophagus PREPULSID increases oesophageal peristaltic activity and lower oesophageal sphincter tone. PREPULSID decreases oesophageal reflux of gastric contents and improves oesophageal clearance. Stomach PREPULSID increases gastric and duodenal contractility and antroduodenal co-ordination. PREPULSID decreases duodenogastric reflux. PREPULSID accelerates gastric and duodenal emptying. Intestinal region PREPULSID enhances intestinal propulsive activity and accelerates small and large bowel transit. Other effects: Due to its lack of direct cholinomimetic effects, PREPULSID does not increase basal and pentagastrin induced gastric aci Read the complete document